mad1

Mad1 (6-21) is a peptide fragment derived from the Mad1 protein, specifically encompassing residues 6 to 21. This fragment exhibits binding affinity towards the mammalian Sin3A PAH2 domain, with a Kd value of approximately 29 nM.

Mad1 (6-21) TFA，作为Mad1蛋白的6-21片段，与哺乳动物Sin3A PAH2结合，其Kd约为29 nM。

ML347 (LDN 193719) 是一种选择性的 ALK1/ALK2 抑制剂，它们的 IC50 分别为 46/32 nM，比对 ALK3 的抑制性高 300 倍。

Astragaloside II (Astrasieversianin VIII) 是一种分离自黄芪中的天然化合物。

Zilurgisertib fumarate (INB-000928 fumarate) 是一种高效且选择性的激活素受体样激酶 2 (ALK2/ACVR1) 抑制剂。它能够显著抑制 ALK2 的激酶活性（IC50 = 15 nM），并下调由 BMP-6 诱导的 SMAD1/5 磷酸化（IC50 = 63 nM）。Zilurgisertib 通过阻断 ALK2 介导的信号传导，可抑制肝细胞中铁调素 (hepcidin) 的产生（IC50 = 20 nM），从而调节铁代谢。在临床前研究中，Zilurgisertib 在癌症诱发贫血模型中展现出改善贫血的潜力，能有效增加血红蛋白水平。

Dalbergioidin exhibits tyrosinase inhibitory activity with an IC50 of 20 mM. It shows a melanin biosynthesis inhibition zone in the culture plate of Streptomyces bikiniensis that has commonly been used as an indicator organism. Dalbergioidin protects MC3T3-E1 osteoblastic cells against H2O2-induced cell damage through activation of the PI3K/AKT/SMAD1 pathway, suggests that it may be useful in bone metabolism diseases, particularly osteoporosis. Dalbergioidin also ameliorates doxorubicin-induced renal fibrosis by suppressing the TGF-β signal pathway.